Taylor Wessing has released the May 2013 edition of its Cambridge Technology and Life Sciences Update.
Taylor Wessing has added a fresh batch of data-protection-focused content to its Global Data Hub site.
Health Alert — 6 May 2013 download
The 6 May 2013 issue of DLA Piper’s Health Alert publication is available now.
Health Alert — 13 May 2013 download
The 13 May 2013 issue of DLA Piper’s Health Alert publication is available now.
Healthcare advertising in the UAE download
Many changes are afoot in respect of healthcare and pharmaceuticals in the UAE. There is a real push to improve standards relating to health and medicine across the board.
DLA Piper has advised Healthcare Buying Group on its acquisition of DBG (UK) from Synova Capital.
Patients First and Foremost, the government’s initial response to the Francis Report, was published just before Easter.
This article offers some simple tools to help guide compliance officers, executives, new lawyers and others in evaluating whether Stark may prohibit a proposed or existing arrangement.
The spring 2013 issue of Walker Morris’s Procurement Update covers topics such as the EU procurement reforms, the Utilities Directive and NHS healthcare services.
The Life Sciences Law Review explores legal issues of special interest to pharmaceutical, biotechnology and medical device companies in 27 jurisdictions.
OIG’s ‘Special Fraud Alert on Physician-Owned Entities’ is the strongest statement to date that investing in or doing business with a POD is a significant Antikickback law risk.
The government has launched a consultation on whether NHS organisations should be made subject to compulsory data protection audits.
A raft of Irish, UK and US firms have won roles on the battle for control of Irish biotechnology company Elan, which yesterday rejected an offer from Royalty Pharma.
Henry Carr QC, sitting as a deputy High Court judge in the Patents Court, has made only the second reference to the CJEU for a preliminary ruling on the patentability of stem cells.
This briefing is intended to cut through the pages of small print and to see where CCGs will stand in the new world order when it comes to planning and securing services for patients.
In Resolution v Lundbeck, Arnold J has allowed Resolution Chemicals Ltd to pursue its own revocation proceedings against Lundbeck’s SPC/GB02/049 protecting escitalopram.
Taylor Wessing has released the April 2013 edition of Synapse, its publication dedicated to law for life sciences.
Hogan Lovells’ global life-sciences practice has been placed in band one for the second year running in the Chambers and Partners Global 2013 rankings.
Mourant Ozannes has advised a consortium of investors on the £700m sale and leaseback of 12 UK private hospitals from the Spire Healthcare Group.
The US Food and Drug Administration is undergoing a major culture change, and nowhere is that impact being felt more than in the food industry.
The latest issue of Data & Information E-Alerts is available now from Addleshaw Goddard.
Interpretation of section 25 of the Self Regulation Code of Marketing Communication.
The CMS provides stakeholders with the opportunity to comment on certain aspects of the Sunshine final rule that were not raised in the proposed rule.
Comparative advertising in the UAE.
Arnold J says the SPC system is dysfunctional as it cannot be applied consistently by local patent offices.
This month on Synapse, Taylor Wessing discusses the impact of insolvency on licensors and licensees in the life sciences sector.
Medical device alert download
The US FDA has issued new draft guidance on distinguishing medical device recalls from product enhancements.
Taylor Wessing discusses injunctions against pharma patent infringement.
Chinese SOE unable to extricate itself from US antitrust litigation against vitamin C exporters download
Judge’s decision illustrates the risks that Chinese parent companies face when doing business in the US through affiliates.
The Curtis Life Sciences group provides a wide range of legal services to clients in the life sciences sector, including manufacturers, funds and institutions.
Our pharma team is highly knowledgeable about the process of development, testing and commercialisation of pharmaceutical products and their entire lifecycle.
China trade marks — inclusion of retail and wholesale services relating to medicines and pharmaceuticals download
The China Trade Marks Office recently announced that from 1 January 2013 it is accepting applications to register trade marks in relation to retail or wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies only in class 35.
Welcome to the Fall/Winter 2012 issue of our China Life Sciences Newsletter, a periodic update on key developments, companies, and people in the dynamic China life sciences industry.
The heart of a marketing authorisation application is the pre-clinical and clinical data that proves the drug’s safety and efficacy.
On 6 December 2012, the EU Court of Justice dismissed AstraZeneca’s appeal of the General Court’s judgment in AstraZeneca v Commission.
The general counsel of Swiss generic drugmaker Actavis is to step down from the role as US rival Watson Pharmaceuticals acquires the company for €4.25bn (£3.4bn).
Weight Watchers has launched a tender process for a UK and Europe healthcare panel as the slimming group prepares to expand its business of working with state and commercial organisations in the sector.
US firms Latham & Watkins, Skadden Arps Meagher & Flom, Sullivan & Cromwell and Weil Gotshal & Manges have all won roles advising on Valeant Pharmaceuticals’ $2.6bn (£1.6bn) acquisition of dermatology drugmaker Medicis Pharmaceutical.
Field Fisher Waterhouse (FFW) has launched a representative office in Silicon Valley in a bid to clinch work originating in the Californian technology hub.
Clifford Chance and Linklaters were part of a string of City firms advising on private equity group Cinven’s £465m acquisition of generic drugs company Mercury Pharma from HgCapital.
FCPA update — July 2012 download
In this issue: the SFO’s latest bribery related settlement; The difficulty of recovering damages from the government when an FCPA prosecution misfires; German High Court ruling on pharmaceutical industry and doctors.
Novartis has announced the results of its first panel review since the company’s $40bn takeover of Alcon, with three magic circle firms – Allen & Overy, Freshfields Bruckhaus Deringer and Linklaters – securing spots on the global roster along with two US firms.
The Royal Pharmaceutical Society (RPS) is looking to put together its first legal panel, with the move coming shortly after the arrival of its first general counsel.
Hogan Lovells has boosted its global life sciences practice with the hire of partner Carla Schoonderbeek and her team of five associates from NautaDutilh.
CMS Cameron McKenna and Freshfields Bruckhaus Deringer secured prize mandates on the €9.6bn (£8.4bn) sale of Swiss drug company Nycomed to the Japanese Takeda Pharmaceutical Company.
A quartet of international firms has scooped lead roles as French pharmaceutical giant Sanofi-Aventis finalised its $20.1bn (£12.47bn) acquisition of US company Genzyme.
Despite global economic conditions, deal-making by large pharmaceutical companies has remained relatively buoyant, say Daniel Pavin, Grant Castle and Alexandra Pygall.
The UK life sciences industry is a world leader, but the lack of appetite from domestic investors is potentially threatening the development of life-saving medicines, says Simon Wallwork
Beachcroft is to install a healthcare consultancy unit after appointing the former chair of the Healthcare Commission Sir Ian Kennedy as a consultant.
Kurt Geiger general counsel Suzanne Smith is to leave the company to return to the pharmaceuticals sector, joining global biotechnology corporation Genzyme.
Willkie Farr & Gallagher has advised US dermatology company Stiefel Laboratories on its $3.6bn (£2.5bn) takeover by pharmaceutical giant GlaxoSmithKline (GSK)